Cargando…
A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress
Although beta-amyloid (Aβ) and phosphorylated tau remain the preferred targets for disease-modifying treatments (DMT) against Alzheimer’s disease (AD), part of the pathophysiological mechanisms of cognitive impairment are related to neuroinflammation and oxidative stress. In mild cognitive impairmen...
Ejemplares similares
-
Sex, Neuropsychiatric Profiles, and Caregiver Burden in Alzheimer’s Disease Dementia: A Latent Class Analysis
por: Rosende-Roca, Maitée, et al.
Publicado: (2022) -
Antiapoptotic Effects of EGb 761
por: Serrano-García, Norma, et al.
Publicado: (2013) -
The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
por: Rosende-Roca, Maitee, et al.
Publicado: (2021) -
Managing Clinical Trials for Alzheimer’s Disease During the COVID-19 Crisis: Experience at Fundació ACE in Barcelona, Spain
por: Abdelnour, Carla, et al.
Publicado: (2020) -
The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment
por: Marquié, Marta, et al.
Publicado: (2023)